SANGAMO THERAPEUTICS, INC. (SGMOQ) Free cash flow 2016–2025
SANGAMO THERAPEUTICS, INC. (SGMOQ) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$97.3MFY2025 · since FY2016: -$66.6M → -$97.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$97.3M | -44.4% |
| FY2024 | -$67.4M | +72.6% |
| FY2023 | -$246.0M | -0.9% |
| FY2022 | -$243.8M | +5.0% |
| FY2021 | -$256.5M | -265.3% |
| FY2020 | $155.2M | +194.0% |
| FY2019 | -$165.1M | -2433.8% |
| FY2018 | -$6.5M | -187.7% |
| FY2017 | $7.4M | +111.2% |
| FY2016 | -$66.6M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More SGMOQ financial trends
SGMOQ RevenueSGMOQ Net incomeSGMOQ Net marginSGMOQ Gross profitSGMOQ Gross marginSGMOQ Operating incomeSGMOQ Operating marginSGMOQ Operating cash flowSGMOQ Capital expendituresSGMOQ Return on equitySGMOQ Stock buybacksSGMOQ Dividends paidSGMOQ Total assetsSGMOQ Total liabilitiesSGMOQ Shareholders’ equitySGMOQ overview →